¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"syncytial giant cell hepatitis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • balloon cell nevus
    dz¼±¼¼Æ÷¸ð¹Ý
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
  • ciliated cell
    ¼¶¸ð¼¼Æ÷
  • clear cell
    Åõ¸í¼¼Æ÷
  • clear cell acanthoma
    Åõ¸í¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, Åõ¸í¼¼Æ÷±Ø¼¼Æ÷Á¾
  • clear cell adenocarcinoma
    Åõ¸í¼¼Æ÷»ù¾ÏÁ¾, Åõ¸í¼¼Æ÷¼±¾ÏÁ¾
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
  • clear cell hidradenoma
    Åõ¸í¼¼Æ÷¶¡»ùÁ¾
  • clear cell sarcoma
    Åõ¸í¼¼Æ÷À°Á¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
  • cell bank
    ¼¼Æ÷ÀºÇà
  • nerve cell body
    ½Å°æ¼¼Æ÷ü
  • cell
    ¼¼Æ÷
  • cell culture
    ¼¼Æ÷¹è¾ç
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell death
    ¼¼Æ÷»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • giant lichenification
    °Å´ëż±È­
  • giant magnet
    °Å´ëÀÚ¼®(ÊÙËöËÛ).
  • giant magnet
    °Å´ëÀÚ¼®(¡­í¸à´).
  • giant melanosome
    °Å´ë¸á¶ó´Ñ ¼Òü
  • giant metamyelocyte
    °Å´ëÈİñ¼ö¼¼Æ÷(¡­ý­ÍéâÐá¬øà).
  • giant nerve fiber
    °Å´ë½Å°æ¼¶À¯.
  • giant papillary conjunctivitis
    °Å´ëÀ¯µÎ°á¸·¿°
  • giant potential
    °Å´ëÀüÀ§(ËÝÓÞï³êÈ).
  • giant retinal tear
    °Å´ë¸Á¸·¿­°ø
  • giant rugae
    Å«ÁÖ¸§, °Å´ëÃߺ®(¡­õáÛü).
  • giant sigmoid
    °Å´ëS»ó°áÀå.
  • giant solitary trichoepithelioma
    °Å´ë ´Ü¹ß¼º ¸ð³¶ »óÇÇÁõ
  • giant thrombocyte
    °Å´ëÇ÷¼ÒÆÇ(?Ì´ËÛ̬).
  • giant tooth
    °Å´ëÄ¡(¡­öÍ).
  • giant ulcer
    °Å´ë ±Ë¾ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • chronic hepatitis B
    ¸¸¼º BÇü °£¿°
  • chronic persistent hepatitis
    ¸¸¼º Áö¼Ó¼º °£¿°
  • delta (¥ä) hepatitis virus
    µ¨Å¸°£¿°¹ÙÀÌ·¯½º
  • delta hepatitis
    µ¨Å¸°£¿°(DÇü°£¿°)(¡­ÊÜæú)
  • delta hepatitis.
    d Çü °£¿°, µ¨Å¸°£¿°
  • drug-induced hepatitis
    ¾à¹°¼º °£¿°(¡­°£¿°).
  • drug-induced hepatitis
    ¾à¹° [¼ÒÈ­]¾à¹°¼º °£¿°(¡­ÊÜæú).
  • drug-induced hepatitis
    ¾à¹° ¼ÒÈ­¾à¹°¼º °£¿°(¡­ÊÜæú).
  • epidemic hepatitis
    À¯Ç༺ °£¿°.
  • epizootic hepatitis
    µ¿¹°À¯Ç༺ °£¿°.
  • fulminant hepatitis
    Àü°Ý¼º °£¿°
  • fulminant hepatitis
    Àü°Ý¼º °£¿°.
  • fulminant hepatitis
    Àü°Ý¼º°£¿°(¡­ÊÜæú)
  • fulminating hepatitis
    Àü°Ý¼º °£¿°.
  • granulomatous hepatitis
    À°¾ÆÁ¾¼º °£¿°.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Satellite cell
    ½Å°æÀý¾Æ±³¼¼Æ÷ [À§¼º¼¼Æ÷]
    [¿¾ ¿ë¾î] À§¼º¼¼Æ÷
  • Cardiac muscle cell
    ½ÉÀå±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ½É±Ù¼¼Æ÷
  • Glial cell
    ¾Æ±³¼¼Æ÷
    [¿¾ ¿ë¾î] ±³¼¼Æ÷
  • Glial cell process
    ¾Æ±³¼¼Æ÷µ¹±â
    [¿¾ ¿ë¾î] ±³¼¼Æ÷µ¹±â
  • Glial cell body
    ¾Æ±³¼¼Æ÷ü
    [¿¾ ¿ë¾î] ±³¼¼Æ÷ü
  • Ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¾Æ¸Þ¹Ù¾ç¼¼Æ÷
  • Dark cell
    ¾îµÎ¿î¼¼Æ÷
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷
  • Dark cell
    ¾îµÎ¿î¼¼Æ÷
    [¿¾ ¿ë¾î] ¾ÏÁÖ¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø±âÁ¾(¹è)¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø±âÁ¾¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
  • Columnar ependymal cell
    ¿øÁÖ³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ»óÀǼ¼Æ÷
  • Columnar epithelial cell
    ¿øÁÖ»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ»óÇǼ¼Æ÷
  • Columnar cell
    ¿øÁÖ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ¼¼Æ÷
  • Type II hair cell
    ¿øÁÖÅм¼Æ÷
    [¿¾ ¿ë¾î] ÀüÆÄ¿¬Á¢¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • T suppressor cell
    T ¾ï¾Ð¼¼Æ÷(åääâá¬øà)
  • unit cell
    ´ÜÀ§(Ó¤êÈ) ¼¼Æ÷ (á¬øà)
  • vegetative cell
    Áõ½ÄÇü(ñòãÖúþ) ¼¼Æ÷ (á¬øà)
  • virgin cell
    ó³à ¼¼Æ÷ (ô¥Ò³á¬øà)
  • X cell
    X ¼¼Æ÷ (á¬øà)
  • XYZ cell theory
    XYZ ¼¼Æ÷(á¬øà) ÀÌ·Ð(×âÖå)
  • Y cell
    Y ¼¼Æ÷ (á¬øà)
  • Z cell
    Z ¼¼Æ÷ (á¬øà)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
GPM general preventive medicine; giant pigmented melanosome
GRW giant ragweed [test]
GSCN giant serotonin-containing neuron
GSN gelsonin; giant serotonin-containing neuron
HGPS hereditary giant platelet syndrome; Hutchinson-Gilford progeria syndrome
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
HAV Anti-Hepatitis A virus
HBV Anti-hepatitis B virus
HCV Anti-hepatitis C virus
anti-HCV Anti-hepatitis-C-virus
anti-HCV Antibodies against hepatitis C virus
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell mediated lympholysis
    ¼¼Æ÷ ¸Å°³ ¸²ÇÁ±¸ ¿ëÇØ
  • cell mediated reaction
    ¼¼Æ÷ ¸Å°³¼º ¹ÝÀÀ
  • cell membrane permeability
    ¼¼Æ÷¸· Åõ°ú¼º
  • cell of parathyroid gland
    ºÎ°©»ó»ù ¼¼Æ÷, ºÎ°©»ó¼± ¼¼Æ÷
  • cell organelles
    ¼¼Æ÷ ¼Ò±â°ü
  • cell physiology
    ¼¼Æ÷ »ý¸®ÇÐ
  • cell pole
    ¼¼Æ÷ ±Ø
  • cell regeneration
    ¼¼Æ÷ Àç»ý
  • cell saver
    Ç÷±¸ ȸ¼ö±â
  • cell sorting
    ¼¼Æ÷ ºÐ·ù
  • cell substitution
    ¼¼Æ÷ ġȯ, Ç÷±¸ Àç»ý
  • cell surface marker
    ¼¼Æ÷ Ç¥¸é Ç¥ÁöÀÚ
  • cell survival curve
    ¼¼Æ÷ »ýÁ¸ °î¼±
  • cell transfer
    ¼¼Æ÷ ÀÌÀÔ
    Á¼Àº Àǹ̿¡¼­´Â °¢Á¾ ¼¼Æ÷¸¦ ¹æ»ç¼± Á¶»ç µîÀÇ Ã³¸®¸¦ °¡ÇÑ µ¿¹°¿¡ ÁÖÀÔÇϰí ÁÖÀÔµÈ ¼¼Æ÷ÀÇ ¼º»óÀ» Á¶»çÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ ¼¼Æ÷ ÁÖÀÔÀÇ ¹æ¹ýÀ» °¡¸®Å°¸ç in vitro¿¡¼­ ¼¼Æ÷ ±â´ÉÀ» Á¶»çÇϱⰡ °ï¶õÇÑ °æ¿ì, in vivo¿¡¼­ÀÇ ¹ÝÀÀ¼ºÀ» Á¶»çÇÏ°í ½ÍÀº °æ¿ì, ¶Ç chimera mouse¸¦ Á¦ÀÛÇÒ ¶§¿¡ »ç¿ëµÈ´Ù. ³ÐÀº Àǹ̿¡¼­´Â ¼¼Æ÷°¡ ÇÑÆí¿¡¼­ ´Ù¸¥ ÆíÀ¸·Î À̵¿ÇÏ´Â °ÍÀ» °¡¸®Å²´Ù.
  • cell typing
    Ç÷±¸Çü °Ë»ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
hepatitis, alcoholic An acute or chronic degenerative and inflammatory lesion of the liver in the alcoholic which is potentially progressive though sometimes reversible. It does not necessarily include steatosis, fibrosis, or cirrhosis of alcoholics, although it is frequently associated with these conditions. It is characterised by liver cell necrosis, infiltration by polymorphonuclear leukocytes and lymphocytes, and mallory bodies. The morphologic changes of chronic alcoholic hepatitis are not likely to be confused with chronic hepatitis (hepatitis, chronic).
(12 Dec 1998)
hepatitis antibodies Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis.
(12 Dec 1998)
hepatitis antigens Antigens from any of the hepatitis viruses including surface, core, and other associated antigens.
(12 Dec 1998)
hepatitis-associated antigen A term used for the surface antigen of hepatitis B virus before its nature was established.
See: hepatitis B surface antigen.
(05 Mar 2000)
hepatitis, autoimmune An unresolving, predominately periportal, hepatitis, usually with hypergammaglobulinaemia and serum autoantibodies. The existence of subgroups (types 1, 2, and 3) based on serological findings are controversial. Additionally, some patients have variant forms, where there are features associated with both autoimmune hepatitis and another type of chronic liver disease (overlap syndromes) or where there are findings incompatible with autoimmune hepatitis (outlier syndromes).
(12 Dec 1998)
hepatitis A virus <virology> An RNA virus (hepatovirus) in the family Picornaviridae, that is the causative agent of viral hepatitis type A.
The virus replicates in hepatocytes and is presumed to reach the intestine via the bile duct. Transmission occurs by the faecal-oral route.
Synonym: infectious hepatitis virus.
(20 Sep 2002)
hepatitis B <virology> A form of viral hepatitis, known as serum hepatitis, because it is commonly spread through contact with infected blood products (transfusion). May also be spread sexually or from mother to infant. Hepatitis B can cause a much more severe infection than hepatitis A and can occur as an asymptomatic carrier state, a chronic infection or as cirrhosis of the liver. Those at risk (IV drug abusers, health care workers, dialysis patients, transfusion recipients, homosexuals) should be immunised with hepatitis B vaccine.
The virus is 42nm diameter, with an outer sheath enclosing inner 27nm core particle containing the circular viral DNA. Aggregates of the envelope proteins are found in plasma and are referred to as hepatitis B surface antigen (HBsAg, previously called Australia antigen). The virus can persist for long periods (and in asymptomatic carriers), association of integrated virus with hepatocellular carcinoma is now well established.
(27 Sep 1997)
hepatitis B antibodies <immunology> Antibodies to the hepatitis b antigens, including antibodies to the surface (Australia) and core of the dane particle and those to the "e" antigens.
(12 Dec 1998)
hepatitis B antigen Antigens of the virion of the hepatitis b virus or the dane particle, its surface, core and other associated antigens, like the hbe antigen.
(12 Dec 1998)
hepatitis b, chronic An inflammatory disease of the liver caused by hepatitis b virus and lasting six months or more.
(12 Dec 1998)
hepatitis B core antigen <virology> (HBcAb, HBcAg), the antigen found in the core of the Dane particle (which is the complete virus) and also in hepatocyte nuclei in hepatitis B infections.
(05 Mar 2000)
hepatitis B e antigen (HBeAb, HBe, HBeAg), an antigen, or group of antigen's, associated with hepatitis B infection and distinct from the surface antigen (HBsAg) and the core antigen (HBcAg); it is associated with the viral nucleocapsid. Its presence indicates that the virus is replicating and the individual is potentially infectious.
(05 Mar 2000)
hepatitis b e antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis b or in virulent chronic hepatitis b, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins g.
(12 Dec 1998)
hepatitis b immunization Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Healthcare workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
hepatitis B surface antigen <virology> A serologic marker on the surface of the hepatitis B virus. The body will normally produce antibodies to hepatitis B surface antigen as part of the normal immune response to infection. It is the presence of antibodies to the hepatitis B surface antigen that are detected in a positive hepatitis B blood test.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á